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The hypothesis that an infection plays a role in the etiology of Hodgkin's disease (HD) is
suggested by both its clinical and histologic features. Its bimodal age-incidence pattern also
suggests an infectious process among younger persons. In economically advantaged populations,
the first peak occurs among young adults, while in disadvantaged populations, it occurs among
children at a much lower frequency. It appears that the age distribution of HD shadows that of
susceptibility to common childhood infections, such as the Epstein-Barr virus (EBV); further-
more, that riskofHD is increased among thosesusceptible toa relatively lateinfection, in parallel
with infectious mononucleosis (IM), and it has been found that people who have had IM have
about three times theexpected rateofHD. Serologically, there is aconsistent association between
EBV and HD. As a group, patients have an altered antibody pattern against EBV which suggests
chronic reactivation, both following and preceding diagnosis. This altered pattern is common to
all age groups. Severity of infection may alter host control among younger people, while
diminished cellular immunity with aging may allow similar reactivation among older persons.
Whether the EBV plays a direct role or simply reflects the action of a more primary factor is
unknown.
The hypothesis that the pathogenesis of Hodgkin's disease (HD) involves an
infectious agent has been considered since it was first described by Thomas Hodgkins
in 1832 [1-2]. This is suggested primarily by its clinical features ofnight sweats, fever,
and lymphadenopathy, as well as histologic features resembling an inflammatory
granuloma. Historically, the classification ofHD has been a matter ofcontention. The
frequent coexistence of active tuberculosis was taken as evidence of its infectious
nature [1]. Evidence ofits malignant nature include metastatic spread, transplantabil-
ity, and the aneuploidy and clonality of the diagnostic Reed-Sternberg cell [3]. An
early proponent of the Epstein-Barr virus (EBV) as a candidate agent was Dr. Alfred
Evans [4], and it has been my privilege to collaborate with him for nearly 15 years in
assessing the role of EBV in the etiology of HD. This paper reviews Dr. Evans's
contribution in this research.
HD is a relatively rare disease, the age-adjusted incidence (per 100,000 person-
years) being 2.9 for white Americans and 1.6 for blacks. Generally, rates are higher
among males. Because of its unusual age distribution, the majority ofdiagnoses occur
before age 45 [5]. Recent advances in treatment have dramatically improved survival
rates, so that current expectation for five-year survival is 74 percent, nearly twice that
ofthe early 1960s [6].
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Theepidemiologic featuresofHD also suggest aninfectiousetiology in several ways.
Most malignancies have an age incidence curve which exponentially increases in the
last decades oflife. In contrast, HD has a bimodal age-incidence curve with an initial
peak occurring in young adulthood in industrialized populations, and the second
among the oldest persons (Fig. 1). In economically developing populations, however,
the first peak occurs in childhood, almost exclusively among boys, and little disease is
diagnosed among young adults. Transition populations have intermediate patterns
[7].
As first suggested by Newell in 1970, this geographic variation among younger
people in relation to economic conditions is quite reminiscent of the epidemiology of
paralytic polio (PP) in the pre-vaccine era, in which risk ofdisease with infection was
greater among adolescents and adults than among children [8]. In the polio model,
socioeconomic conditions were associated with the age-incidence of PP, as these
affected the age at which people were infected with these widespread viruses. Age at
infection, in turn, determined the likelihood of developing neurologic complications.
Most infections produced no or inapparent disease and resulted in life-long immunity.
Paralysis was generally rare with infection in preschool children. At older ages, the
probability increased directly with age. Thus, in developing countries, most PP was
seen among infants because essentially all were infected quite early in life. In
economically advantaged populations, PP was seen among older children and young
adults, reflecting an increase in susceptibility to later infection because of better
sanitary conditions and less crowding. For both HD and PP, age-incidence patterns
vary geographically with level of economic development. For both, disease risk is
greatest among young children from the least favorable environment but greatest
among adolescents and young adults from the most favorable. For both, a temporal
upward shift in the age-incidence pattern has accompanied economic development.
Analogy suggests that HD among young adults may also be related to the effect of
delayed age at infection with a common childhood virus [9]. The reported associations
of risk of HD among young adults with risk factors associated with higher social class
support this hypothesis [10,11].
The bimodality ofthe age-incidence curve of HD as well as the observation that, in
contrast to younger persons, there was little geographic or temporal variation in the
incidence among older persons, suggested to MacMahon in 1957 that there may be
separate etiologies operating in the two age groups. He noted that the relative
proportion of males was higher among older persons and that being Jewish was a risk
factor among older people, but not apparently so among young adults [12].
Evidence that young and older patients differed clinically also supports the
two-disease hypothesis. In terms ofthe histologic sub-types, the nodular sclerotic form
predominates among younger people and themixed-cellularity form among older [13].
Eosinophilic infiltrates are much more common in the young, while atypical mitoses
and other features ofmalignancy are more common in the old [14]. Older patients are
more likely to have abdominal lesions and less likely to have mediastinal involvement
[15,16]. However, others have interpreted these features as reflecting age- and
sex-associated host response to a common neoplastic process [17].
Theepidemiologic features ofHD among young adults werealso reminiscent ofthat
of infectious mononucleosis (IM), a disease for which Dr. Evans was instrumental in
proving the role of delayed EBV infection, as both are diseases of young adults in
economically advantaged populations [18]. The similarities prompted Dr. Evans to
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propose in 1971, "Perhaps some cases of HD represent either the host's response to
EBV infection that is delayed until the early twenties or a secondary response in
persons with a genetic susceptibility or an impaired immunologic system, or both"
[4].
The association between HD and EBV is supported by two sets offindings. The first
concerns the consistent finding ofincreased risk ofsubsequent diagnosis ofHD among
personswho have beendiagnosed with IM. In six published studies which followed over
41,000 individuals with a serologic diagnosis of IM, a total of 37 HD cases were
observed, with 12 expected [19-24].
The second set of findings concerns elevated titers of antibodies against the major
determinants of the EBV. These include the viral capsid antigen (VCA); antibodies
against the VCA are commonly measured as evidence of EBV infection. In addition,
antibodies against the early antigen (EA) are present during primary infection and
during reactivation. Two EA antibody components can be distinguished: the diffuse
(D) which is elevated in nasopharyngeal carcinoma, and the restricted (R) which is
elevated in Burkitt's lymphoma. A final determinant is the nuclear antigen (EBNA)
which is a virus-induced antigen expressed in lymphocytes which carry the EBV
genome, i.e., "transformed" B cells [25].
The most common finding was that HD patients as a group had elevated titers
against the VCA in comparison to controls, who generally were patients with other
diseases or blood donors [26-41]. Several studies also reported elevated titers against
EA [29-30,34-28]. None of these studies were analyzed for confounding by the
various antibodies nor for history of IM. Although several studies evaluated effect
modification among the histologic sub-categories, no consistent variation was evident.
In the late 1970s, Dr. Evans evaluated the serologic association between the EBV
and HD in two separate investigations conducted in Sao Paulo, Brazil. In the first, the
antibody profiles of67 cases werecompared to that of67 healthycontrols, matched for
age, sex, and socioeconomic status [42]. In this study, the patients had a significantly
elevated titer distribution against the VCA as well as a significantly higher proportion
with antibodies against the EA, indicative ofvirus activation. In addition, the subjects
were compared for their antibody response to nine other common infections, and no
differences were found. In a second study, Dr. Evans compared 70 cases to 161 oftheir
relatives, each of whom was paired to a population control. Again the cases had
elevated antibody patterns in comparison to both related and unrelated controls. In
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addition, those relatives ofcases with elevated antibody levels had significantly higher
titers than those relatives ofcases with lower EBV levels [43].
It was during the mid-1970s that our collaboration began in a large, population-
based, case-control study of Hodgkin's disease conducted in the combined metropoli-
tan areas of Boston and Worcester, Massachusetts. This study included 326 newly
diagnosed cases aged 15 years or older, and two control groups. The first comprised
650 controls identified by a randomizing procedure from the population base with a
comparable age and sex distribution to thecases. The purposeofthiscontrol group was
for the analysis ofinterview information, with the aim ofidentifying risk factors which
influence or reflect delayed susceptibility to common childhood infections. A second
comparison included 315 siblings ofcases. Thiscontrolgroupwas used fortheserologic
component of the study. The use of siblings eliminated differences in childhood social
environment.
The details of the interview study have been published elsewhere [44,45]. In brief,
we found that among young adults (15-39 years of age), risk of HD was associated
with small family size and early birth order, high maternal education, and low density
housing in childhood-all factors which would favor susceptibility to "late" infections.
Similar risk factors held for middle-aged persons (40-54 years). Among older persons,
however, risk was independent of these social class variables. The latter finding again
suggests that the pathogenesis of HD among older persons is independent of that
among younger persons.
The details of the serologic study have also been published [46]. These analyses
involved the 304 cases and 285 siblings for whom blood specimens were obtained.
Again we found that risk of HD was significantly associated with elevated titers of
anti-VCA and both components of the EA. On multivariate analysis based on the
matched data, risk among those with elevated VCA antibodies (>1:320) was more
than four times that of persons with low titers (s 1:40). For the EA, elevated titers
against the D component were associated with a twofold risk. These findings held true
for all age groups. The study also found a significant elevation of titers against the
cytomegalovirus (CMV), but not consistently so among all age and sex groups.
The most interesting finding was an association ofantibody level and history of IM
among both cases and controls. Among cases, 35 reported a history ofIM. Ofthese, 66
percent had elevated titers against VCA compared to 32 percent ofthe 227 cases who
had no history. Similarly among the sibling controls, 17 percentofthe 23 with a history
of IM had elevated VCA antibodies compared to 12 percent of 227 sibling controls
without. A parallel finding was true for elevated levels ofantibodies against the EA-D;
the results for cases were 46 percent and 27 percent, respectively, and for the siblings,
30 percent and 10 percent. It is important to note that essentially all thesesubjects had
had an EBV infection. It is likely that those who reported having IM had had the
infection on average somewhat later in life than those who had had an unrecognized
EBV infection. Thus the finding supports the hypothesis that higher VCA antibodies
are associated with a more severe EBV infection [47], which is associated with age at
infection.
At this point it was clear that the serologic association between EBV and HD was
valid, but whether it was itselfprimary, or simply secondary to the effects oftreatment
or to the immune dysfunction of the disease itself was not known. The only way to
evaluate the latter explanation would be to determine the antibody status of a sample
of cases during the latent period-that is, between infection with EBV and the
diagnosis of HD. It was at this point that Dr. Evans's long-standing interest and
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activity in theestablishment ofserum banks as thebasis for follow-upstudies related to
infectious exposure provided the means to an end.
The first step was to do a pilot study. Dr. Evans contacted his long-time colleague,
Dr. George Comstock of Johns Hopkins University. Dr. Comstock had established a
serum bank in 1974 for 25,802 participants of the Washington County (Maryland)
population study of determinants of cancer. This population had been prospectively
kept under surveillance for subsequent diagnoses. Dr. Evans asked Dr. Comstock if
there were any participants who had developed HD and, if so, to send their sera and
that of matched controls to Yale for analysis. Three sets of case and control sera
arrived. For two sets, the cases had clearly altered patterns ofantibodies against EBV
in blood drawn 11 and 21 months prior to diagnosis. In order to evaluate specificity,
antibodies against three other herpesviruses-CMV, simplex, and varicella-were
assayed; no differences were apparent. The third set was normal; it was from a case of
histocytic lymphoma [48].
Armed with the promise of the pilot study, a large, multi-center collaboration was
organized to search for additional serum specimens which had been drawn and stored
from people who later developed HD. Because of Dr. Evans's extensive network of
colleagues, a collaboration was established which together held blood specimens from
over 240,000 individuals for whom subsequent diagnoses of malignancy could be
determined either from computerized medical records or bydirectfollow-up which was
being done for other purposes. The details ofthis study will be published elsewhere. In
summary, we found serum specimens stored prior to a diagnosis of HD of 43 persons.
These were matched to specimensdrawn at the sametime from 96 controls ofthe same
age and sex. For the cases, the specimens were obtained in the period 13 years to eight
months prior to diagnosis. We found that the antibodies against VCA and the diffuse
form of EA were significantly elevated among cases with a three- and fourfold risk,
respectively. In addition, cases were distinguished by elevated antibodies against
EBNA and by the presence of IgA antibodies against the VCA. The pattern seen in
these pre-diagnosis specimens, like that in the post-diagnosis specimens, suggested
chronic EBV replication.
Although other risk factors differ between age groups, altered EBV antibodies are
common to all. Severity ofinfection may result in altered host control among younger
people, while diminished cellular immunity with aging may allow similar reactivation
among older people. The observation of HD occurring in relation to infection with the
human immunodeficiency virus, which also allows a high level of EBV reactivation,
would support this proposal [49,50].
Whether chronic EBV replication has a direct role in pathogenesis is not at all clear.
The lack of evidence of virus DNA in involved tissue [51,52] argues against direct
genetic damage by the virus. It is conceivable, however, that this chronic antigenic
stimulation may lead to altered gene expression, resulting in the immune dysfunction
and cellular abnormality of HD [53]. An alternative explanation is that the chronic
EBV expression is secondary to another, more fundamental factor, such as another
viral infection. Whatever the solution of this question, our understanding of the
etiology of HD has been greatly enhanced by the contribution ofDr. Evans.
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